Literature DB >> 19329116

Revised FIGO staging for carcinoma of the vulva.

Neville F Hacker1.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19329116     DOI： 10.1016/j.ijgo.2009.02.011

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN： 0020-7292            Impact factor:   3.561


× No keyword cloud information.
  21 in total

1.  International Federation of Gynecology and Obstetrics (FIGO) staging system revised: what should be considered critically for gynecologic cancer?

Authors:  Hee Seung Kim; Yong Sang Song
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

Review 2.  Primary malignant melanomas of the female lower genital tract: clinicopathological characteristics and management.

Authors:  Dongying Wang; Tianmin Xu; He Zhu; Junxue Dong; Li Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer.

Authors:  Merlijn Hutteman; Joost R van der Vorst; Katja N Gaarenstroom; Alexander A W Peters; J Sven D Mieog; Boudewijn E Schaafsma; Clemens W G M Löwik; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer
Journal:  Am J Obstet Gynecol       Date:  2011-07-30       Impact factor: 8.661

4.  Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: time to reconsider the FIGO staging system?

Authors:  Nikhil G Thaker; Ann H Klopp; Anuja Jhingran; Michael Frumovitz; Revathy B Iyer; Patricia J Eifel
Journal:  Gynecol Oncol       Date:  2014-12-16       Impact factor: 5.482

5.  Investigation of the clinicopathological features of squamous cell carcinoma of the vulva: a retrospective survey of the Tohoku Gynecologic Cancer Unit.

Authors:  Masayuki Futagami; Yoshihito Yokoyama; Kaori Iino; Masahiko Aoki; Tadahiro Shoji; Toru Sugiyama; Hisanori Ariga; Hideki Tokunaga; Tadao Takano; Yoh Watanabe; Nobuo Yaegashi; Keiichi Jingu; Naoki Sato; Yukihiro Terada; Akira Anbai; Tsuyoshi Ohta; Hirohisa Kurachi; Yuuki Kuroda; Hiroshi Nishiyama; Keiya Fujimori; Takafumi Watanabe; Hisashi Sato; Toru Tase; Hitoshi Wada; Hideki Mizunuma
Journal:  Int J Clin Oncol       Date:  2015-02-24       Impact factor: 3.402

6.  [Changes in the TNM classification of gynecological tumors].

Authors:  L-C Horn; M W Beckmann; A Beller; D Schmidt; U Ulrich; P Hantschmann; C Wittekind
Journal:  Pathologe       Date:  2010-09       Impact factor: 1.011

7.  Optimization of near-infrared fluorescent sentinel lymph node mapping in cervical cancer patients.

Authors:  Joost R van der Vorst; Merlijn Hutteman; Katja N Gaarenstroom; Alexander A W Peters; J Sven D Mieog; Boudewijn E Schaafsma; Peter J K Kuppen; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer
Journal:  Int J Gynecol Cancer       Date:  2011-11       Impact factor: 3.437

8.  Vulvar cancer in Botswana in women with and without HIV infection: patterns of treatment and survival outcomes.

Authors:  Emily MacDuffie; Sruthi Sakamuri; Rebecca Luckett; Qiao Wang; Memory Bvochara-Nsingo; Barati Monare; Lisa Bazzett-Matabele; Thabo Moloi; Tlotlo Ralefala; Doreen Ramogola-Masire; Sanghyuk S Shin; Nicola M Zetola; Surbhi Grover
Journal:  Int J Gynecol Cancer       Date:  2021-09-07       Impact factor: 3.437

9.  Perineural Invasion Correlates With Common Pathological Variables and Clinical Outcomes of Patients With Squamous Cell Carcinoma of the Vulva Treated With Primary Radical Surgery and Inguinal-femoral Lymphadenectomy.

Authors:  Angiolo Gadducci; Sabina Pistolesi; Stefania Cosio; Chiara Comunale; Antonio Fanucchi; Antonio Giuseppe Naccarato
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

10.  Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer.

Authors:  Nicole D Fleming; Pamela T Soliman; Shannon N Westin; Ricardo dos Reis; Mark Munsell; Ann H Klopp; Michael Frumovitz; Alpa M Nick; Kathleen Schmeler; Pedro T Ramirez
Journal:  Int J Gynecol Cancer       Date:  2015-10       Impact factor: 3.437
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.